A Randomized, Open, Multi-center Phase IIb/III Clinical Study to Assess the Efficacy and Safety of Surufatinib Compared to Capecitabine in Advanced or Metastatic Biliary Tract Carcinoma (BTC) Patients
Latest Information Update: 04 Mar 2022
At a glance
- Drugs Surufatinib (Primary) ; Capecitabine
- Indications Biliary cancer; Cholangiocarcinoma; Gallbladder cancer
- Focus Proof of concept; Registrational; Therapeutic Use
- Sponsors Hutchison MediPharma; HUTCHMED
Most Recent Events
- 30 Jul 2020 According to a Chi-Med media release, interim data from this study is expected in remaining 2020 or early 2021.
- 29 Mar 2019 According to a Chi-Med media release, the first patient was dosed on March 22, 2019 in China.
- 27 Mar 2019 Status changed from not yet recruiting to recruiting.